India has reversed course and granted approval to Gilead Sciences Inc's (GILD.O) patent for its hepatitis C drug Sovaldi, marking a setback for patient groups who said the move could stop affordable copies of the drug. The drug, which has a list price of $1,000 a pill in the United States, was rejected for a patent by the Indian patent authority in January 2015 on the basis it represented only minor changes to a previous formulation, and the company alrea
The decision is a major blow to the access to drug movement, says MSF In direct contradiction to its earlier order, the Controller General of Patents, Designs and Trademark granted American pharmaceutical company Gilead Sciences the patent for the blockbuster Hepatitis C drug Sofosbuvir (brand name Sovaldi) in India. An application for the same patent was first rejected in January 2015 as lacking inventiveness and novelty. On Monday, however, the pa...
Chinese people in the past have gone to the U.S. to for cancer treatment and have snatched up cold medicine and painkillers on trips to Japan. Chinese now go overseas for another medical purpose: curing their liver diseases.Although treatment of the virus has gone through revolutionary development in the last few years, none of the direct-acting antiviral agents which have shown to cure more than 90% of patients within a few months, have yet been approved
Growing numbers of New Zealanders are getting backdoor access to revolutionary hepatitis C drugs at a fraction of the cost.More than 90 percent of people treated with the drugs Sovaldi and Harvoni are cured of hepatitis C, which causes liver disease and autoimmune disorders, but at $NZ1500 per tablet the treatment is prohibitively expensive for most New Zealanders.The recommended 12-week course of the drugs costs more than $140,000.Although Pharmac is gett
GENEVA, January 20, 2016 /PRNewswire/ --Four companies to help speed access to curative direct-acting antiviral in 112 low- and middle-income countries The Medicines Patent Pool (MPP) announced its first round of sub-licences for the generic production of Bristol-Myers Squibb's daclatasvir, a novel direct-acting antiviral that is proven to help cure multiple genotypes of the hepatitis C virus. Generic companies Cipla, Emcure, Hetero and Natco have signed n